Velusetrag

Generic Name
Velusetrag
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C25H36N4O5S
CAS Number
866933-46-2
Unique Ingredient Identifier
J4VNV64ARB
Background

Velusetrag has been used in trials studying the treatment of Gastroparesis and Alzheimer's Disease. It is a highly selective serotonin receptor agonist effective in patients with chronic constipation. It is being developed by Theravance. Velusetrag was discovered by Theravance through the application of its multivalent drug design in a research program dedic...

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).

Phase 2
Active, not recruiting
Conditions
Chronic Intestinal Pseudo-obstruction
Interventions
Drug: Velusetrag
Drug: Placebo
First Posted Date
2023-02-13
Last Posted Date
2023-02-13
Lead Sponsor
Alfasigma S.p.A.
Target Recruit Count
17
Registration Number
NCT05724069
Locations
🇧🇪

UZ Leuven Gasthuisberg Campus, Leuven, Belgium

🇮🇹

Policlinico S.Orsola-Malpighi, Bologna, Italy

🇮🇹

Aou Arcispedale Sant'Anna Di Cona, Cona, Italy

and more 1 locations

The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study

Phase 2
Completed
Conditions
Gastroparesis
Interventions
Drug: Placebo
Drug: Velusetrag
First Posted Date
2014-10-17
Last Posted Date
2018-04-17
Lead Sponsor
Theravance Biopharma
Target Recruit Count
233
Registration Number
NCT02267525

Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects

Phase 1
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: Placebo
Drug: Velusetrag
First Posted Date
2011-11-09
Last Posted Date
2014-12-03
Lead Sponsor
Theravance Biopharma
Target Recruit Count
40
Registration Number
NCT01467726
Locations
🇺🇸

Comprehensive Clinical Development, Miramar, Florida, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy